alosetron has been researched along with Abdominal Pain in 12 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess long-term safety and efficacy of alosetron in women with severe, chronic diarrhea-predominant IBS and in a subset having more frequent urgency (i." | 9.11 | Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. ( Ameen, VZ; Carter, EG; Chey, WD; Chey, WY; Dukes, GE; Heath, AT; Northcutt, A, 2004) |
| "A randomized, double blind, placebo-controlled dose-ranging study was conducted to assess the efficacy of alosetron in men with diarrhea-predominant irritable bowel syndrome (IBS)." | 9.11 | A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. ( Ameen, VZ; Carter, EG; Chang, L; Dukes, GE; Mayer, EA; McSorley, DJ, 2005) |
| " Direct comparison of primary endpoint results from the alosetron, rifaximin, and eluxadoline pivotal trials is not possible; however, general estimates of efficacy can be made, and these demonstrate similar and significantly greater responses to 'adequate relief' and a composite endpoint of abdominal pain/stool form for each agent compared to placebo." | 8.93 | Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? ( Cash, BD; Earnest, DL; Lacy, BE; Rao, T, 2016) |
| "To assess long-term safety and efficacy of alosetron in women with severe, chronic diarrhea-predominant IBS and in a subset having more frequent urgency (i." | 5.11 | Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. ( Ameen, VZ; Carter, EG; Chey, WD; Chey, WY; Dukes, GE; Heath, AT; Northcutt, A, 2004) |
| "A randomized, double blind, placebo-controlled dose-ranging study was conducted to assess the efficacy of alosetron in men with diarrhea-predominant irritable bowel syndrome (IBS)." | 5.11 | A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. ( Ameen, VZ; Carter, EG; Chang, L; Dukes, GE; Mayer, EA; McSorley, DJ, 2005) |
| "In female irritable bowel syndrome patients with predominant diarrhoea or alternating constipation and diarrhoea, alosetron is effective in treatment of abdominal pain and discomfort and bowel-related symptoms." | 5.09 | Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. ( Camilleri, M; Drossman, DA; Dukes, GE; Heath, A; Kong, S; Mangel, AW; Mayer, EA; McSorley, D; Northcutt, AR, 1999) |
| " Direct comparison of primary endpoint results from the alosetron, rifaximin, and eluxadoline pivotal trials is not possible; however, general estimates of efficacy can be made, and these demonstrate similar and significantly greater responses to 'adequate relief' and a composite endpoint of abdominal pain/stool form for each agent compared to placebo." | 4.93 | Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? ( Cash, BD; Earnest, DL; Lacy, BE; Rao, T, 2016) |
| "Alosetron has been shown to produce statistically significant improvements in abdominal pain, stool consistency, stool frequency and urgency in female IBS patients." | 2.40 | Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. ( Mangel, AW; Northcutt, AR, 1999) |
| "Visceral pain was measured by visceromotor response to colorectal distension, and the effects of alosetron and duloxetine on visceral pain were investigated in SART rats." | 1.42 | Specific alteration of rhythm in temperature-stressed rats possess features of abdominal pain in IBS patients. ( Itomi, Y; Kawamura, T; Tsukimi, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itomi, Y | 1 |
| Kawamura, T | 1 |
| Tsukimi, Y | 1 |
| Cash, BD | 1 |
| Lacy, BE | 1 |
| Rao, T | 1 |
| Earnest, DL | 1 |
| Talley, NJ | 1 |
| Chey, WD | 1 |
| Chey, WY | 1 |
| Heath, AT | 1 |
| Dukes, GE | 3 |
| Carter, EG | 2 |
| Northcutt, A | 1 |
| Ameen, VZ | 2 |
| Chang, L | 1 |
| McSorley, DJ | 1 |
| Mayer, EA | 2 |
| Mearin, F | 1 |
| Pappas, TN | 1 |
| Mangel, AW | 3 |
| Lawson, C | 1 |
| Northcutt, AR | 2 |
| Camilleri, M | 2 |
| Drossman, DA | 1 |
| Heath, A | 1 |
| McSorley, D | 1 |
| Kong, S | 1 |
| Shen, B | 1 |
| Soffer, E | 1 |
| Delvaux, M | 1 |
| Frexinos, J | 1 |
7 reviews available for alosetron and Abdominal Pain
| Article | Year |
|---|---|
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Topics: Abdominal Pain; Anti-Bacterial Agents; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidaz | 2016 |
[Drug treatment of irritable bowel syndrome: an unmet need].
Topics: Abdominal Pain; Analgesics; Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Controlled | 2007 |
Review article: evaluation of drugs in experimental gut distension models.
Topics: Abdominal Pain; Animals; Carbolines; Colonic Diseases, Functional; Disease Models, Animal; Dogs; Ser | 1999 |
Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Topics: Abdominal Pain; Carbolines; Colonic Diseases, Functional; Female; Humans; Male; Randomized Controlle | 1999 |
The challenge of irritable bowel syndrome: creating an alliance between patient and physician.
Topics: Abdominal Pain; Antidepressive Agents; Antidiarrheals; Carbolines; Cholinergic Antagonists; Colonic | 2001 |
Novel medications for the irritable bowel syndrome: motility and sensation.
Topics: Abdominal Pain; Animals; Carbolines; Colonic Diseases, Functional; Constipation; Female; Gastrointes | 2001 |
[Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].
Topics: Abdominal Pain; Animals; Benzyl Compounds; Carbolines; Central Nervous System; Colitis, Ulcerative; | 2001 |
3 trials available for alosetron and Abdominal Pain
| Article | Year |
|---|---|
Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Topics: Abdominal Pain; Carbolines; Chronic Disease; Diarrhea; Double-Blind Method; Female; Gastrointestinal | 2004 |
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Carbolines; Diarrhea; Dose-Response Relationship, Dr | 2005 |
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
Topics: Abdominal Pain; Adult; Canada; Carbolines; Colonic Diseases, Functional; Diarrhea; Dose-Response Rel | 1999 |
2 other studies available for alosetron and Abdominal Pain
| Article | Year |
|---|---|
Specific alteration of rhythm in temperature-stressed rats possess features of abdominal pain in IBS patients.
Topics: Abdominal Pain; Animals; Carbolines; Cold Temperature; Disease Models, Animal; Duloxetine Hydrochlor | 2015 |
Board Review Vignette: Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adult; Anion Exchange Resins; Antidiarrheals; Carbolines; Cholestyramine Resin; Cons | 2016 |